High efficacy of combined PRRT and CAPTEM therapy based on objective response rate (RECIST) in patients with pancreatic and midgut neuroendocrine tumors (NET)

#3267

Introduction: PRRT and chemotherapy might be an option.

Aim(s): The goal of this study was to assess objective response rate (ORR), disease control rate (DCR), clinical response after combined therapy using PRRT and chemotherapy CAPTEM in progressive, advanced, unresectable NET.

Materials and methods: Prospective, single arm, open-label, in patients with histologically proven pancreatic NET (panNET) n=14 and midgut NET n=7 (NCT04194125). All patients had combination therapy with PRRT (177Lu DOTATOC) and CAPTEM, disease status and treatment efficiency were evaluated by clinical assessment, including performance status (PS-ECOG), ORR by RECIST.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Nowicki , Zrajkowska A, Pałucki , Nowicka G,

Keywords: neuroendocrine tumor, pancreatic, midgut, DCR, ORR,